Clinical Labs of Hawaii provides test updates for educational purposes to physicians, specialists, and the general public.
CLH now offers two serological (antibody) assays to support clinical evaluation of patients who may have been previously infected or exposed to SARS-CoV-2.
Effective March 1, 2021, Clinical Labs of Hawaii will be performing Clostridium difficile testing on the Xpert® C. difficile/Epi.
Effective 10/31/2020, Clinical Labs will no longer offer the Streptozyme test (STRZ). The manufacturer is no longer producing the test and no replacement has been offered.
Effective November 2, 2020, Clinical Labs of Hawaii will be performing reflexive titers on all positive RPR specimens. RPR as a stand-alone test will no longer be available.
As required by our accrediting agencies, Clinical Labs of Hawaii requisitions and specimen containers must have a minimum of TWO patient identifiers and MATCH EXACLY.
On August 3, 2020 Clinical Labs of Hawaii will begin offering nasal (anterior nares) collection of SARS-CoV-2 specimens at select locations.
On June 4, 2020, the U.S. Department of Health and Human Services (HHS) published new requirements for patient data collection and reporting for COVID-19 test results. Please review this bulletin for more details.
Please review the Clinical Labs of Hawaii frequently asked questions for answers regarding SARS-CoV-2 (COVID-19) molecular testing specimen types.
On May 19, 2020, Clinical Laboratories of Hawaii (CLH) began testing for SARS-CoV-2, the virus that causes COVID-19, using a new high-throughput system, called the Aptima® SARS-CoV-2 Assay conducted on the Hologic Panther instrument.
Please review guidelines from the federal government’s COVID-19 Uninsured Program.
Please review the Clinical Labs of Hawaii frequently asked questions for answers regarding SARS-CoV-2 (COVID-19) serology testing.
Effective April 30, 2020, Clinical Labs of Hawaii began offering serology testing for SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19).
Beginning March 1, 2020, United Healthcare Insurance will require prior authorization/notification for genetic and molecular testing performed in an outpatient setting.